NICE’s decision not to approve Zytiga ‘frustrating’, says ICR
Zytiga is used for the treatment of newly diagnosed, advanced prostate cancer patients
Read More
Tag: Zytiga
NICE sticks to Zytiga rejection
Around 4,000 men newly diagnosed with high-risk metastatic hormone-sensitive prostate cancer would have been eligible for treatment with the drug
Read More
Zytiga, Ajovy among latest SMC decisions
The group also accepted drugs for primary progressive multiple sclerosis and a rare form of lymphoma.
Read More
NICE rejects Janssen’s Zytiga for early, aggressive prostate cancer
It is looking unlikely that Janssen’s Zytiga plus androgen deprivation therapy and prednisone/prednisolone will become routinely available on the NHS as a first-line treatment for patients with high-risk hormone-sensitive metastatic prostate cancer.
Read More
Janssen’s Zytiga approved for earlier use in prostate cancer
European regulators are allowing earlier use of Janssen’s Zytiga in the treatment pathway for metastatic prostate cancer.
Read More
CHMP backs one generic and six label extensions
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended just one generic medicine for approval at its October meeting.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
